- Home
- FIVE vs ARWR Comparison
FIVE vs ARWR Comparison
Compare FIVE & ARWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FIVE | ARWR |
|---|---|---|
| Founded | 2002 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Department/Specialty Retail Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.9B | 10.1B |
| IPO Year | 2012 | 2009 |
Fundamental Metrics
Financial Performance| Metric | FIVE | ARWR |
|---|---|---|
| Price | $225.24 | $63.25 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 19 | 11 |
| Target Price | ★ $188.89 | $77.55 |
| AVG Volume (30 Days) | 818.4K | ★ 2.7M |
| Earning Date | 03-03-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 99.80 |
| EPS | ★ 2.17 | 0.22 |
| Revenue | ★ $3,876,527,000.00 | $16,142,321.00 |
| Revenue This Year | $24.52 | N/A |
| Revenue Next Year | $10.07 | N/A |
| P/E Ratio | ★ $102.81 | $280.07 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $52.38 | $10.66 |
| 52 Week High | $224.80 | $76.76 |
Technical Indicators
Market Signals| Indicator | FIVE | ARWR |
|---|---|---|
| Relative Strength Index (RSI) | 73.84 | 47.61 |
| Support Level | $136.72 | $60.53 |
| Resistance Level | N/A | $65.59 |
| Average True Range (ATR) | 8.03 | 2.85 |
| MACD | 1.56 | -0.20 |
| Stochastic Oscillator | 87.56 | 44.44 |
Price Performance
Historical ComparisonAbout FIVE Five Below Inc.
Five Below Inc is a specialty value retailer offering merchandise targeted at the tween and teen demographic. The Company's edited assortment of products includes select brands and licensed merchandise. It derives revenue from sales of the Company's merchandise to customers.
About ARWR Arrowhead Pharmaceuticals Inc.
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.